Erasca Receives FDA Fast Track Designation for ERAS-007
Erasca, Inc. (Nasdaq: ERAS) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to ERAS-007 for the treatment of a specific type of cancer.
Want more?
Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.